Compounds > ci 988
Page last updated: 2024-09-02

ci 988 and Alloxan Diabetes

ci 988 has been researched along with Alloxan Diabetes in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ardid, D; Boucher, M; Coudoré-Civiale, MA; Courteix, C; Eschalier, A; Fialip, J; Méen, M1
Boucher, M; Coudoré-Civiale, MA; Courteix, C; Eschalier, A; Fialip, J1
Kamei, J; Zushida, K1
Kamei, J; Nagase, H; Zushida, K1
Boucher, M; Coudoré-Civiale, MA; Eschalier, A; Fournié-Zaluski, MC; Méen, M; Roques, BP1

Other Studies

5 other study(ies) available for ci 988 and Alloxan Diabetes

ArticleYear
Potentiation of morphine and clomipramine analgesia by cholecystokinin -B antagonist CI-988 in diabetic rats.
    Neuroscience letters, 2000, May-26, Volume: 286, Issue:1

    Topics: Analgesia; Analgesics, Opioid; Animals; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Clomipramine; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Indoles; Male; Meglumine; Morphine; Nociceptors; Pain; Pain Threshold; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Time Factors

2000
Spinal effect of the cholecystokinin-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic rats.
    Pain, 2000, Volume: 88, Issue:1

    Topics: Analgesia; Analgesics, Opioid; Animals; Diabetes Mellitus, Experimental; Drug Synergism; Hormone Antagonists; Hyperalgesia; Indoles; Injections, Intravenous; Injections, Spinal; Male; Meglumine; Morphine; Nervous System Diseases; Pain Threshold; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Touch

2000
The role of spinal cholecystokinin B receptors in thermal allodynia and hyperalgesia in diabetic mice.
    Brain research, 2001, Feb-23, Volume: 892, Issue:2

    Topics: Animals; Capsaicin; Cholecystokinin; Diabetes Mellitus, Experimental; Enzyme Activators; Hot Temperature; Hyperalgesia; Indoles; Injections, Spinal; Male; Meglumine; Mice; Mice, Inbred ICR; Nerve Fibers; Nociceptors; Pain; Protein Kinase C; Reaction Time; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Spinal Cord

2001
Role of cholecystokinin in the reduction of endomorphin-2-induced antinociception in diabetic mice.
    European journal of pharmacology, 2001, Mar-23, Volume: 416, Issue:1-2

    Topics: Analgesics; Animals; Behavior, Animal; Cholecystokinin; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Indoles; Injections, Intraventricular; Meglumine; Mice; Mice, Inbred ICR; Nociceptors; Oligopeptides; Pain; Pain Measurement; Sincalide

2001
Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.
    British journal of pharmacology, 2001, Volume: 133, Issue:1

    Topics: Aminopeptidases; Animals; Diabetes Mellitus, Experimental; Disulfides; Drug Synergism; Indoles; Male; Meglumine; Naloxone; Naltrexone; Neprilysin; Pain; Pain Measurement; Phenylalanine; Pressure; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Time Factors; Vocalization, Animal; Weight Loss

2001